TTEC Holdings, a global technology and consulting firm, will announce its third quarter 2026 earnings after market close on November 9, 2026. The company will host a live webcast and investor conference call at 8:30 a.m. ET on November 10, 2026, accessible via its website. This earnings release will provide insights into TTEC's performance in AI-driven customer experience solutions. A replay of the webcast will be available for those unable to attend live.
TTEC Holdings' upcoming Q3 2026 earnings release provides context for technology sector activity. For readers following technology stocks, here is Pluang's market snapshot as of Nov 04, 2026 03:41 WIB: Out of 150 priced US tech stocks, 94 rose and 53 fell. Notable movers include CIFR at USD 8.07 with a 17.64% increase and balanced order activity, CORZ at USD 14.15 up 13.15% with 100% buy orders, and IT at USD 205.93 down 12.55% with 60% buy orders. Typical hold times range from 16 to 66 days.
Nova Klúbburinn hf. has completed a share buyback program, acquiring 122,699,386 shares at an average price of ISK 3.26 per share. The buyback was part of an inverse offer process with valid bids for 159,526,476 shares. The company accepted bids up t...
AMC Entertainment will release its Q3 2026 earnings on Nov. 4, following a year-over-year increase in North American box-office receipts to about $3.1 billion from $2.5 billion in Q3 2025. The quarter featured major film releases like Spider-Man: Bra...
Pomerantz LLP is investigating Erasca, Inc. following the termination of its COO, Nicholas Chetwyn, which led to a nearly 10% drop in the company's stock price. The investigation focuses on whether Erasca and its executives engaged in securities frau...
Pomerantz LLP is investigating claims against Yiren Digital Ltd. for possible securities fraud following the company's disclosure of a 34% revenue decline and a significant net loss in Q4 2025. The company also reported increased delinquency rates an...
Pomerantz LLP is investigating Syndax Pharmaceuticals following the company's announcement that its Phase 2 trial for axatilimab in idiopathic pulmonary fibrosis failed to meet its primary endpoint. This news caused Syndax's stock to drop by 2.59% on...
